Maria O. Olza-De

Lausanne Branch
Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 11, 2026

Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.

Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 24, 2025

Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.

Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.

Journal: Frontiers in pharmacology

Published: November 01, 2023

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.

Journal: Immunity

Published: August 18, 2023

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Journal: International journal of molecular sciences

Published: June 05, 2023

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.

Journal: BMC cancer

Published: October 26, 2022

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 24, 2022

Low-dose irradiation for reversing immunotherapy resistance: how to translate?

Low-dose irradiation for reversing immunotherapy resistance: how to translate?

Journal: Journal for immunotherapy of cancer

Published: June 09, 2022

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.

Journal: The Lancet. Oncology

Published: March 08, 2022

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Journal: Journal for immunotherapy of cancer

Published: January 08, 2022

A promising platform for predicting toxicity.

A promising platform for predicting toxicity.

Journal: eLife

Published: September 17, 2021

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 05, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026